ImageneBio (NASDAQ:IMA) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of ImageneBio (NASDAQ:IMA) from a hold rating to a strong sell rating in a research report report published on Saturday.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings initiated coverage on shares of ImageneBio in a research note on Wednesday, October 22nd. They issued a “sell (e-)” rating for the company. Leerink Partnrs raised ImageneBio to a “strong-buy” rating in a research note on Friday, October 24th. Wedbush cut their price target on ImageneBio from $25.00 to $23.00 and set a “neutral” rating on the stock in a report on Friday, July 25th. Leerink Partners started coverage on ImageneBio in a report on Friday, October 24th. They set an “outperform” rating and a $30.00 price objective for the company. Finally, Zacks Research lowered ImageneBio from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $26.50.

ImageneBio Stock Performance

Shares of IMA stock opened at $7.70 on Friday. ImageneBio has a fifty-two week low of $7.24 and a fifty-two week high of $23.28. The stock has a 50 day simple moving average of $8.22 and a two-hundred day simple moving average of $12.61. The company has a market cap of $30.88 million, a P/E ratio of -0.95 and a beta of 0.42.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.91) EPS for the quarter, missing the consensus estimate of ($1.47) by ($1.44). On average, research analysts predict that ImageneBio will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On ImageneBio

A number of institutional investors and hedge funds have recently bought and sold shares of IMA. BML Capital Management LLC lifted its stake in ImageneBio by 3.5% during the 1st quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock valued at $4,750,000 after acquiring an additional 124,937 shares in the last quarter. Deep Track Capital LP purchased a new position in ImageneBio during the third quarter worth about $7,160,000. Blue Owl Capital Holdings LP bought a new stake in ImageneBio in the 3rd quarter worth about $4,409,000. Atlas Venture Life Science Advisors LLC purchased a new stake in ImageneBio in the 3rd quarter valued at about $3,079,000. Finally, Aldebaran Capital LLC bought a new position in shares of ImageneBio during the 1st quarter worth approximately $317,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.